Nom du produit:2-Methoxy-4-(4-morpholinyl)-5-nitrobenzenamine
IUPAC Name:2-methoxy-4-(morpholin-4-yl)-5-nitroaniline
- CAS：1903010-18-3
- Formule moléculaire：C11H15N3O4
- Pureté：95%+
- Numéro de catalogue：CM1078119
- Poids moléculaire：253.26
| Unité d'emballage |
Stock disponible |
Prix($) |
Quantité |
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:1903010-18-3
- Formule moléculaire:C11H15N3O4
- Point de fusion:-
- Code SMILES:O=N(=O)C1=CC(N)=C(OC)C=C1N2CCOCC2
- Densité:1.326±0.06 g/cm3
- Numéro de catalogue:CM1078119
- Poids moléculaire:253.26
- Point d'ébullition:498.9±45.0 °C
- N° Mdl:
- Stockage:
Category Infos
- Morpholines
- Morpholine contains secondary amine groups and has all the typical reactive characteristics of secondary amine groups. It can react with inorganic acids to form salts, and react with organic acids to form salts or amides, which can be subjected to alkylation reaction, and can also be reacted with ethylene oxide, ketone or Willgerodt reaction. Morpholine is a six-membered ring containing oxygen and nitrogen, and its alkalinity is much lower than that of its parent piperidine. The marketed morpholine drugs are mainly distributed in the fields of tumors, cardiovascular and cerebrovascular diseases, respiratory system diseases, digestive system diseases, infectious diseases and mental disorders.
- morpholine price
- if you are interested in morpholine price, please feel free to contact us. More information of our products will be forwarded to you upon receipt of your specific inquiry.
Column Infos
- Lazertinib
- Johnson & Johnson announced new data from the Phase 2 PALOMA-2 study evaluating subcutaneous (SC) amivantamab combined with lazertinib as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations. These data showed a comparable response rate in patients treated with SC amivantamab and lazertinib compared to those treated with the intravenous (IV) formulation in the MARIPOSA study, which established the combination of amivantamab and lazertinib as superior to osimertinib. Lazertinib is an oral, third-generation, brain-penetrant EGFR tyrosine kinase inhibitor (TKI) that targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Recherche 
+86 21 5895 0110 
